WO2001085131A3 - Lipid carrier compositions for improved drug retention - Google Patents

Lipid carrier compositions for improved drug retention Download PDF

Info

Publication number
WO2001085131A3
WO2001085131A3 PCT/CA2001/000655 CA0100655W WO0185131A3 WO 2001085131 A3 WO2001085131 A3 WO 2001085131A3 CA 0100655 W CA0100655 W CA 0100655W WO 0185131 A3 WO0185131 A3 WO 0185131A3
Authority
WO
WIPO (PCT)
Prior art keywords
improved drug
mol
drug retention
retention
liposomes
Prior art date
Application number
PCT/CA2001/000655
Other languages
French (fr)
Other versions
WO2001085131A2 (en
Inventor
Lawrence D Mayer
Dos Nancy Santos
Marcel B Bally
Murray Webb
Paul Tardi
Original Assignee
Celator Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Technologies Inc filed Critical Celator Technologies Inc
Priority to AU2001258106A priority Critical patent/AU2001258106A1/en
Publication of WO2001085131A2 publication Critical patent/WO2001085131A2/en
Publication of WO2001085131A3 publication Critical patent/WO2001085131A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Abstract

Substantially cholesterol-free liposomes are provided which demonstrate improved drug retention in vivo. These liposomes may comprise: (a) at least 60 mol.% of a phospholipid comprising two saturated fatty acids, the acyl chain of each being the same or different, at least one of said acyl chains having more than 18 carbon atoms; (b) from about 2 to about 15 mol.% hydrophilic polymer-conjugated lipids; and (c) up to about 38 mol.% of one or more vesicle-forming lipids. Specific embodiments of this invention are liposomes encapsulating idarubicin or topotecan and demonstrating improved drug retention. Also provided is a method for determining whether retention of a particular drug may be improved by this invention.
PCT/CA2001/000655 2000-05-11 2001-05-11 Lipid carrier compositions for improved drug retention WO2001085131A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001258106A AU2001258106A1 (en) 2000-05-11 2001-05-11 Lipid carrier compositions for improved drug retention

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20339900P 2000-05-11 2000-05-11
US60/203,399 2000-05-11

Publications (2)

Publication Number Publication Date
WO2001085131A2 WO2001085131A2 (en) 2001-11-15
WO2001085131A3 true WO2001085131A3 (en) 2002-04-25

Family

ID=22753830

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2001/000655 WO2001085131A2 (en) 2000-05-11 2001-05-11 Lipid carrier compositions for improved drug retention

Country Status (2)

Country Link
AU (1) AU2001258106A1 (en)
WO (1) WO2001085131A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI235066B (en) 2001-10-03 2005-07-01 Celator Technologies Inc Liposome loading with metal ions
CA2527130A1 (en) * 2003-04-02 2004-10-14 Paul Tardi Pharmaceutical compositions containing active agents having a lactone group and transition metal ions
AU2005291807B2 (en) * 2004-10-06 2012-04-19 Bc Cancer Agency Liposomes with improved drug retention for treatment of cancer
WO2006052767A2 (en) 2004-11-05 2006-05-18 Inex Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal camptothecin formulations
CN101795671A (en) * 2007-08-21 2010-08-04 阿尔扎公司 Liposome compositions for in vivo administration of boronic acid compounds
US10980798B2 (en) 2011-11-03 2021-04-20 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
WO2013067449A1 (en) 2011-11-03 2013-05-10 Taiwan Liposome Company, Ltd. Pharmaceutical compositions of hydrophobic camptothecin derivatives
US20150202153A1 (en) * 2012-10-04 2015-07-23 University Of The Witwatersrand, Johannesburg Liposomal drug delivery system

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5213804A (en) * 1989-10-20 1993-05-25 Liposome Technology, Inc. Solid tumor treatment method and composition
WO1993019738A1 (en) * 1992-03-27 1993-10-14 Liposome Technology, Inc. Method of treatment of infected tissues
WO1998034597A1 (en) * 1997-02-06 1998-08-13 Duke University Liposomes containing active agents
WO2000023052A1 (en) * 1998-09-16 2000-04-27 Alza Corporation Liposome-entrapped topoisomerase inhibitors
US6171613B1 (en) * 1996-10-01 2001-01-09 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5213804A (en) * 1989-10-20 1993-05-25 Liposome Technology, Inc. Solid tumor treatment method and composition
WO1993019738A1 (en) * 1992-03-27 1993-10-14 Liposome Technology, Inc. Method of treatment of infected tissues
US6171613B1 (en) * 1996-10-01 2001-01-09 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
WO1998034597A1 (en) * 1997-02-06 1998-08-13 Duke University Liposomes containing active agents
WO2000023052A1 (en) * 1998-09-16 2000-04-27 Alza Corporation Liposome-entrapped topoisomerase inhibitors

Also Published As

Publication number Publication date
WO2001085131A2 (en) 2001-11-15
AU2001258106A1 (en) 2001-11-20

Similar Documents

Publication Publication Date Title
Adamich et al. Phospholipid activation of cobra venom phospholipase A2. 2. Characterization of the phospholipid-enzyme interaction
WO2001085131A3 (en) Lipid carrier compositions for improved drug retention
CA2180872A1 (en) Composition containing nucleic acids, preparation and uses
DE60108184D1 (en) Process for the preparation of fatty acid esters
WO2005070466A3 (en) Liposome composition for delivery of therapeutic agents
Ginsburg et al. The effect of ferriprotoporphyrin IX and chloroquine on phospholipid monolayers and the possible implications to antimalarial activity
CA2438116A1 (en) Amphoteric liposomes and the use thereof
ID18276A (en) FATTY ACID ESTER MAKING METHOD
IL145117A0 (en) Encapsulation of bioactive complexes in liposomes
EP2119771A3 (en) Proteins
DE60023531D1 (en) SPECIFIC ACYLATED GYLCEROL COMPOUNDS AS SOFTENERS FOR POLYMERS
ATE283836T1 (en) METHOD FOR PRODUCING FATTY ACID ESTERS
EE200200289A (en) Method for the preparation of alkyl esters of fatty acids
DE69922243D1 (en) SOLID LIPID NANOSPHERES SUITABLE FOR A FAST INTRODUCTION IN CELLS
ID29876A (en) COMPOSITION THAT CONTAIN diphosphonate acids
DE69924383D1 (en) PROCESS FOR THE PREPARATION OF FROZEN FATTY FOOD EMULSIONS
AU2003219558A1 (en) Method for extracting lipid mixture containing phospholipids comprising polyunsaturated fatty acids from viscera of fish
EP2295556A3 (en) Lipolytic enzymes variants and methods for their production
Van den Bosch et al. The acylation of 1-acylglycero-3-phosphorylcholines by rat-liver microsomes
WO2001079216A3 (en) Polyamide nucleic acid derivatives, agents and methods for producing them
NO983520L (en) Process for the preparation of lysophosphatidylcholine
ID27856A (en) PROCESS FOR PREPARATION OF BENZOIC ACID DERIVATES IN ORTHO-ALKILATION
EA200401565A1 (en) METHOD FOR OBTAINING CARDIOLYPINE OR ANALOGUE OF CARDIOLIPINE (OPTIONS), METHOD FOR OBTAINING LIPOSOME AND COMPOSITION OF CARDIOLIPINE FOR TREATING DISEASES (OPTIONS)
Arthur et al. The distribution and acyl composition of plasmalogens in guinea pig heart
ATE288587T1 (en) METHOD FOR DETERMINING LIPID UPtake

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP